Has the Danish Biotech Industry valuation changed over the past few years?

Investors are pessimistic on the Danish Biotechs industry, indicating that they anticipate long term growth rates will be lower than they have historically. The industry is trading at a PE ratio of 11.7x which is lower than its 3-year average PE of 25.6x. The 3-year average PS ratio of 6.0x is higher than the industry's current PS ratio of 3.7x.

Which industries have driven the changes within the Danish Healthcare industry?

There are no additional sub-industries under this industry.

Danish (OMX) Biotech Industry Analysis

Date	Market Cap	Revenue	Earnings	PE	Absolute PE	PS
Tue, 21 Jul 2026	DKK 148.9b	DKK 40.8b	DKK 12.9b	11.9x	11.6x	3.6x
Thu, 18 Jun 2026	DKK 134.8b	DKK 40.6b	DKK 12.8b	11.8x	10.5x	3.3x
Sat, 16 May 2026	DKK 140.4b	DKK 40.3b	DKK 12.8b	12.3x	11x	3.5x
Mon, 13 Apr 2026	DKK 145.9b	DKK 39.2b	DKK 13.9b	11.1x	10.5x	3.7x
Wed, 11 Mar 2026	DKK 143.2b	DKK 40.1b	DKK 15.0b	5.9x	9.5x	3.6x
Fri, 06 Feb 2026	DKK 166.1b	DKK 40.4b	DKK 18.9b	6.2x	8.8x	4.1x
Sun, 04 Jan 2026	DKK 171.7b	DKK 40.6b	DKK 19.0b	6.2x	9x	4.2x
Tue, 02 Dec 2025	DKK 175.7b	DKK 40.8b	DKK 19.1b	6x	9.2x	4.3x
Thu, 30 Oct 2025	DKK 166.7b	DKK 39.1b	DKK 16.8b	13x	9.9x	4.3x
Sat, 27 Sep 2025	DKK 162.7b	DKK 38.9b	DKK 16.8b	12.5x	9.7x	4.2x
Mon, 25 Aug 2025	DKK 145.1b	DKK 38.8b	DKK 16.8b	11.1x	8.7x	3.7x
Wed, 23 Jul 2025	DKK 125.3b	DKK 26.8b	DKK 7.3b	11.3x	17.2x	4.7x
Fri, 20 Jun 2025	DKK 128.1b	DKK 27.3b	DKK 7.4b	11x	17.2x	4.7x
Sun, 18 May 2025	DKK 125.0b	DKK 28.0b	DKK 7.9b	10.1x	15.8x	4.5x
Tue, 15 Apr 2025	DKK 125.1b	DKK 27.3b	DKK 7.7b	11.1x	16.3x	4.6x
Thu, 13 Mar 2025	DKK 148.4b	DKK 27.3b	DKK 7.7b	12.1x	19.3x	5.4x
Sat, 08 Feb 2025	DKK 153.8b	DKK 26.0b	DKK 4.7b	15.5x	32.8x	5.9x
Mon, 06 Jan 2025	DKK 165.3b	DKK 26.0b	DKK 4.7b	17.5x	35.2x	6.4x
Wed, 04 Dec 2024	DKK 164.2b	DKK 26.0b	DKK 4.7b	16.9x	35x	6.3x
Fri, 01 Nov 2024	DKK 174.6b	DKK 25.5b	DKK 5.5b	21.1x	31.9x	6.8x
Sun, 29 Sep 2024	DKK 180.2b	DKK 25.5b	DKK 5.5b	22.3x	32.9x	7.1x
Tue, 27 Aug 2024	DKK 198.8b	DKK 25.5b	DKK 5.5b	25.5x	36.3x	7.8x
Thu, 25 Jul 2024	DKK 200.7b	DKK 24.8b	DKK 5.6b	18.6x	35.6x	8.1x
Sat, 22 Jun 2024	DKK 176.3b	DKK 24.8b	DKK 5.6b	16.7x	31.3x	7.1x
Mon, 20 May 2024	DKK 183.8b	DKK 24.8b	DKK 5.6b	19.1x	32.6x	7.4x
Wed, 17 Apr 2024	DKK 183.3b	DKK 23.9b	DKK 5.0b	19.4x	36.4x	7.7x
Fri, 15 Mar 2024	DKK 193.2b	DKK 23.9b	DKK 5.0b	20x	38.4x	8.1x
Sun, 11 Feb 2024	DKK 169.1b	DKK 23.3b	DKK 4.2b	23x	40.6x	7.3x
Tue, 09 Jan 2024	DKK 180.6b	DKK 23.3b	DKK 4.2b	26.2x	43.4x	7.7x
Thu, 07 Dec 2023	DKK 180.1b	DKK 23.3b	DKK 4.2b	26.2x	43.3x	7.7x
Sat, 04 Nov 2023	DKK 161.8b	DKK 22.0b	DKK 4.7b	19.2x	34.1x	7.3x
Mon, 02 Oct 2023	DKK 194.6b	DKK 22.0b	DKK 4.7b	23x	41.1x	8.8x
Wed, 30 Aug 2023	DKK 201.8b	DKK 22.0b	DKK 4.7b	24x	42.7x	9.2x
Fri, 28 Jul 2023	DKK 196.2b	DKK 19.5b	DKK 4.4b	35x	44.5x	10x


DK Market	0.65%
Healthcare	0.97%
Biotech	-1.57%
Biotech	-1.57%

Company	Last Price	7D	1Y	Valuation
ZEAL Zealand Pharma	DKK 297.30	5.8% +DKK 1.2b	-14.9%	PE3.3x
BIOPOR BioPorto	DKK 1.17	12.5% +DKK 64.4m	-14.6%	PS14.4x
STRAP Strategic Partners	DKK 635.00	7.6% +DKK 1.9m	-41.2%	PS85.7x

Announcement • Jul 07

Genmab Announces Tepkinly in Combination with Lenalidomide and Rituximab Is Approved by the European Commission for the Treatment of Relapsed or Refractory Follicular Lymphoma

Genmab announced that the European Commission (EC) granted marketing authorization for TEPKINLY (epcoritamab) in combination with lenalidomide and rituximab (TEPKINLY + R2) for the treatment of adult patients with relapsed or refractory (R/R) follicular lymphoma (FL). The approval is based on results from the pivotal Phase 3 EPCORE FL-1 trial that evaluated fixed-duration TEPKINLY + R2 compared to standard of care R2. TEPKINLY (epcoritamab) plus lenalidomide and rituximab (R2) is the first and only bispecific-based therapy approved in Europe for the treatment of follicular lymphoma in the second-line setting, offering a chemotherapy-free option. In the Phase 3 EPCORE FL-1 trial, fixed-duration TEPKINLY + R2 demonstrated significantly superior progression-free survival and overall response rates compared to R2, with approximately three out of four patients achieving a complete response. The marketing authorization is supported by data from the Phase 3 EPCORE FL-1 trial, an open-label interventional trial to evaluate the safety and efficacy of TEPKINLY + R2 compared to R2 alone in patients with R/R FL. The study demonstrated TEPKINLY + R2 reduced the risk of disease progression or death by 79% (HR 0.21, 95% CI: 0.13 - 0.33, p2(95% CI: 72.7, 87.7; p<.0001). Among patients who were treated with TEPKINLY + R2, 74% achieved a complete response (CR) (n=181/243, 95% CI: 68.5, 79.8) compared to a 43% CR rate among patients treated with R2 (n=106/245, 95% CI: 37.0, 49.7). The safety profile of TEPKINLY + R2 in the EPCORE FL-1 study was consistent with the known safety profiles of the individual regimens (epcoritamab and R2). In the trial, the most common (= 20%) adverse reactions were neutropenia, rash, upper respiratory tract infections, fatigue, diarrhea, injection site reactions, anemia, constipation, thrombocytopenia, cytokine release syndrome (CRS), hypogammaglobulinemia, COVID-19, pyrexia, and pneumonia. Serious adverse reactions occurred in 44% of patients who received epcoritamab in combination with lenalidomide and rituximab. Serious adverse reactions in = 5% of patients included CRS, pneumonia, COVID-19, and febrile neutropenia. The marketing authorization of TEPKINLY + R2 by the European Commission represents a pivotal moment for individuals living with follicular lymphoma, providing a treatment option at first relapse, when effective intervention is critical. FL is typically a slow-growing form of non-Hodgkin lymphoma (NHL) that arises from B-cell lymphocytes. FL is the second most common form of NHL overall, accounting for 20-30 percent of all NHL cases. FL incidence is significantly higher in European populations, 11-29 percent, compared to non-European populations, 2-18 percent. FL is considered incurable, and there is no standard of care treatment for third-line or later FL. Patients who achieve remission also often experience relapse. EPCORE FL-1 (NCT05409066) is a Phase 3 open-label interventional trial to evaluate the safety and efficacy of epcoritamab plus lenalidomide and rituximab (R2) versus R2 alone in patients with relapsed/refractory (R/R) follicular lymphoma (FL). The Phase 3 EPCORE FL-1 study included patients with relapsed or recurrent FL following at least one prior line of treatment across a broad range of patient characteristics and disease risk factors. Patients were randomized to receive epcoritamab in combination with R2 (n=243) or R2 alone (n=245). Patients received epcoritamab in 28-day cycles for a total of 12 cycles or until disease progression or unacceptable toxicity, whichever occurred first. Efficacy was established based on the dual primary endpoints of progression free survival (PFS) and overall response rate (ORR) determined by Lugano 2014 criteria as assessed by Independent Review Committee (IRC). Additional efficacy outcome measures include complete response (CR) and duration of response (DOR). The pivotal Phase 3 EPCORE FL-1 trial results were published in The Lancet in January 2026. Epcoritamab is an IgG1-bispecific antibody created using Genmab's proprietary DuoBody technology and administered subcutaneously. Genmab's DuoBody-CD3 technology is designed to direct cytotoxic T cells selectively to elicit an immune response toward target cell types. Epcoritamab is designed to simultaneously bind to CD3 on T cells and CD20 on B cells and induces T-cell-mediated killing of CD20+ cells. Epcoritamab (approved under the brand name EPKINLY in the U.S. and Japan, and TEPKINLY in the European Union) has received regulatory approval in certain lymphoma indications in more than 65 territories. Epcoritamab is being co-developed by Genmab and AbbVie as part of the companies' oncology collaboration. The companies share commercial responsibilities in the U.S. and Japan, with AbbVie responsible for further global commercialization. Both companies will pursue additional international regulatory approvals for the investigational relapsed or refractory (R/R) follicular lymphoma (FL) indication and additional approvals for the R/R diffuse large B-cell lymphoma (DLBCL) indication. Genmab and AbbVie continue to evaluate the use of epcoritamab as a monotherapy, and in combination, across lines of therapy in a range of hematologic malignancies. This includes several Phase 3, open-label, randomized trials, including a trial evaluating epcoritamab in combination with R-CHOP in adult patients with newly diagnosed DLBCL (NCT05578976), a trial evaluating epcoritamab in combination with lenalidomide compared to chemotherapy infusion in patients with R/R DLBCL (NCT06508658), and a trial evaluating epcoritamab in combination with lenalidomide and rituximab (R2) compared to chemoimmunotherapy in patients with previously untreated FL (NCT06191744). The safety and efficacy of epcoritamab has not been established for these investigational uses. Tepkinly (epcoritamab) as monotherapy is indicated for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) after two or more lines of systemic therapy. Tepkinly in combination with lenalidomide and rituximab is indicated for the treatment of adult patients with relapsed or refractory follicular lymphoma (FL). Tepkinly as monotherapy is indicated for the treatment of adult patients with relapsed or refractory follicular lymphoma (FL) after two or more lines of systemic therapy.

Danish (OMX) Biotech Industry Analysis

Industry Valuation and Performance

Industry Trends

Top Stock Gainers and Losers

Latest News

Bavarian Nordic’s Chikungunya Vaccine Application Filed With Brazilian Regulator Anvisa

ZEAL: Obesity Program Execution Will Support Future Upside Beyond Reset Expectations

Genmab Announces Tepkinly in Combination with Lenalidomide and Rituximab Is Approved by the European Commission for the Treatment of Relapsed or Refractory Follicular Lymphoma

Bioporto A/S Un-changes Earnings Guidance for the Full Year 2026

New minor risk - Financial data availability